Novel Automated Chemiluminescent Immunoassay for the Detection of Autoantibodies Against Aquaporin-4 in Neuromyelitis Optica Spectrum Disorders

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2025 Feb 13

PMID 39941228

Authors

Nozomi Yamazaki

Toshiyuki Takahashi

Tatsuro Misu

Yukihiro Nishikawa

Affiliations

Soon will be listed here.

Abstract

: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune-related neurological disease that primarily affects the optic nerve and spinal cord. According to current international consensus guidelines for NMOSD, confirming the presence of aquaporin-4 immunoglobulin G antibody (AQP4-IgG) is one of the most important diagnostic criteria because AQP4-IgG is a significant diagnostic biomarker of NMOSD. Several assays are currently available for detecting AQP4-IgG, including cell-based assays (CBAs) and enzyme-linked immunosorbent assays (ELISAs). However, each assay has certain disadvantages, including insufficient sensitivity and specificity, the need for sophisticated techniques, and semi-quantitative results. : We developed a fully automated chemiluminescent enzyme immunoassay (CLEIA) to detect AQP4-IgG (AQP4-CLEIA). This assay utilizes the recombinant antigen purified from the newly generated AQP4-M23 stably expressing Chinese hamster ovary cell line and an anti-AQP4 monoclonal antibody as a calibrator. : In analytical performance studies, the assay demonstrates good precision and linearity over the entire measurement range. Moreover, this assay showed no high-dose hook effect and interference from endogenous substances. In clinical validation studies, patients with AQP4-IgG positive NMOSD, multiple sclerosis, or myelin oligodendrocyte glycoprotein antibody-associated disorder and healthy individuals were tested. A cutoff value of 10.0 U/mL was determined by receiver operating characteristic curves based on the results of a microscopic live CBA. The sensitivity and specificity for AQP4-IgG-positive NMOSD were 97.0% and 100.0%, respectively, at the cutoff value. : The results suggest that AQP4-CLEIA is a convenient automated method for measuring AQP4-IgG titers in hospitals and clinical laboratories, offering an effective alternative to the gold-standard CBA.

References

Werten P, Hasler L, Koenderink J, Klaassen C, de Grip W, Engel A . Large-scale purification of functional recombinant human aquaporin-2. FEBS Lett. 2001; 504(3):200-5. DOI: 10.1016/s0014-5793(01)02703-x. View

Miyazaki K, Abe Y, Iwanari H, Suzuki Y, Kikuchi T, Ito T . Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4. J Neuroimmunol. 2013; 260(1-2):107-16. DOI: 10.1016/j.jneuroim.2013.03.003. View

Banwell B, Bennett J, Marignier R, Kim H, Brilot F, Flanagan E . Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023; 22(3):268-282. DOI: 10.1016/S1474-4422(22)00431-8. View

Shimizu J, Hatanaka Y, Hasegawa M, Iwata A, Sugimoto I, Date H . IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology. 2010; 75(16):1423-7. DOI: 10.1212/WNL.0b013e3181f8832e. View

Waters P, Reindl M, Saiz A, Schanda K, Tuller F, Kral V . Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2016; 87(9):1005-15. PMC: 5013123. DOI: 10.1136/jnnp-2015-312601. View

Sato D, Nakashima I, Takahashi T, Misu T, Waters P, Kuroda H . Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology. 2013; 80(24):2210-6. DOI: 10.1212/WNL.0b013e318296ea08. View

Tanaka R, Takemura M, Sato M, Yamada Y, Nakagawa T, Horibe T . Comparison of chemiluminescence enzyme immunoassay (CLEIA) with ELISA for the determination of anti-cyclic citrullinated peptide antibodies. Clin Chim Acta. 2009; 411(1-2):22-5. DOI: 10.1016/j.cca.2009.09.032. View

Hiroaki Y, Tani K, Kamegawa A, Gyobu N, Nishikawa K, Suzuki H . Implications of the aquaporin-4 structure on array formation and cell adhesion. J Mol Biol. 2005; 355(4):628-39. DOI: 10.1016/j.jmb.2005.10.081. View

Kimbrough D, Fujihara K, Jacob A, Lana-Peixoto M, Leite M, Levy M . Treatment of Neuromyelitis Optica: Review and Recommendations. Mult Scler Relat Disord. 2014; 1(4):180-187. PMC: 3926208. DOI: 10.1016/j.msard.2012.06.002. View

10.

Cinquanta L, Fontana D, Bizzaro N . Chemiluminescent immunoassay technology: what does it change in autoantibody detection?. Auto Immun Highlights. 2017; 8(1):9. PMC: 5483212. DOI: 10.1007/s13317-017-0097-2. View

11.

Graus F, Titulaer M, Balu R, Benseler S, Bien C, Cellucci T . A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016; 15(4):391-404. PMC: 5066574. DOI: 10.1016/S1474-4422(15)00401-9. View

12.

Papp V, Magyari M, Aktas O, Berger T, Broadley S, Cabre P . Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review. Neurology. 2020; 96(2):59-77. PMC: 7905781. DOI: 10.1212/WNL.0000000000011153. View

13.

Fujio Y, Kojima K, Hashiguchi M, Wakui M, Murata M, Amagai M . Validation of chemiluminescent enzyme immunoassay in detection of autoantibodies in pemphigus and pemphigoid. J Dermatol Sci. 2016; 85(3):208-215. DOI: 10.1016/j.jdermsci.2016.12.007. View

14.

Sato D, Callegaro D, Lana-Peixoto M, Waters P, de Haidar Jorge F, Takahashi T . Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014; 82(6):474-81. PMC: 3937859. DOI: 10.1212/WNL.0000000000000101. View

15.

Prain K, Woodhall M, Vincent A, Ramanathan S, Barnett M, Bundell C . AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD. Front Neurol. 2019; 10:1028. PMC: 6787171. DOI: 10.3389/fneur.2019.01028. View

16.

Tampoia M, Abbracciavento L, Barberio G, Fabris M, Bizzaro N . A new M23-based ELISA assay for anti-aquaporin 4 autoantibodies: diagnostic accuracy and clinical correlation. Auto Immun Highlights. 2020; 10(1):5. PMC: 7065340. DOI: 10.1186/s13317-019-0115-7. View

17.

Hor J, Asgari N, Nakashima I, Broadley S, Leite M, Kissani N . Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020; 11:501. PMC: 7332882. DOI: 10.3389/fneur.2020.00501. View

18.

Westgard J, Carey R, Wold S . Criteria for judging precision and accuracy in method development and evaluation. Clin Chem. 1974; 20(7):825-33. View

19.

Brooking H, Ananieva-Jordanova R, Arnold C, Amoroso M, Powell M, Betterle C . A sensitive non-isotopic assay for GAD65 autoantibodies. Clin Chim Acta. 2003; 331(1-2):55-9. DOI: 10.1016/s0009-8981(03)00088-3. View

20.

Waters P, McKeon A, Leite M, Rajasekharan S, Lennon V, Villalobos A . Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012; 78(9):665-71. PMC: 3286228. DOI: 10.1212/WNL.0b013e318248dec1. View